The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study.
endometrial cancer
low-volume metastasis
recurrence-free survival
sentinel lymph node biopsy
ultrastaging
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Mar 2023
30 Mar 2023
Historique:
received:
19
02
2023
revised:
24
03
2023
accepted:
27
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
The aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an international collaboration including 13 referring institutions. A total of 1428 patients were included in this analysis. One hundred and eighty-six patients (13%) had lymph node involvement. Fifty-nine percent of positive SLN exhibited micrometastases, 26.9% micrometastases, and 14% isolated tumor cells. Seventeen patients with positive lymph nodes did not receive any adjuvant therapy. At a median follow-up of 33.3 months, the disease had recurred in 114 women (8%). Patients with micrometastases in the lymph nodes had a worse prognosis of disease-free survival compared to patients with negative nodes or LVM. The rate of recurrence was significantly higher for women with micrometastases than those with low-volume metastases (HR = 2.61;
Identifiants
pubmed: 37046712
pii: cancers15072052
doi: 10.3390/cancers15072052
pmc: PMC10093146
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol Rep. 2021 Feb 09;36:100720
pubmed: 33732849
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Int J Gynecol Pathol. 2018 May;37(3):242-251
pubmed: 28700425
Gynecol Oncol. 2019 Jun;153(3):670-675
pubmed: 30833134
Gynecol Oncol. 2012 Jun;125(3):531-5
pubmed: 22366409
Gynecol Oncol. 2014 Jan;132(1):44-9
pubmed: 24183734
Eur J Surg Oncol. 2023 Feb 14;:
pubmed: 36801150
Gynecol Oncol. 2021 May;161(2):347-352
pubmed: 33678480
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
J Natl Compr Canc Netw. 2023 Feb;21(2):181-209
pubmed: 36791750
Gynecol Oncol. 2021 Sep;162(3):590-598
pubmed: 34274133
J Natl Compr Canc Netw. 2014 Feb;12(2):288-97
pubmed: 24586087
Gynecol Oncol. 2015 Jan;136(1):54-9
pubmed: 25450151
Mod Pathol. 2010 May;23 Suppl 2:S26-32
pubmed: 20436499
Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6
pubmed: 18226630
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Gynecol Oncol. 2019 Sep;154(3):475-479
pubmed: 31345606
Obstet Gynecol. 2015 Apr;125(4):1006-1026
pubmed: 25798986
Lancet Oncol. 2018 Oct;19(10):1394-1403
pubmed: 30143441
Ann Surg Oncol. 2016 May;23(5):1653-9
pubmed: 26714954
Am J Obstet Gynecol. 2014 Apr;210(4):363.e1-363.e10
pubmed: 24361787
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Clin Transl Oncol. 2020 Aug;22(8):1272-1279
pubmed: 31863354
J Clin Med. 2020 Jun 25;9(6):
pubmed: 32630498
Gynecol Oncol. 2017 Aug;146(2):240-246
pubmed: 28577885
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S9-S24
pubmed: 30550481
Int J Gynecol Cancer. 2020 Oct;30(10):1627-1632
pubmed: 32699021
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Curr Oncol Rep. 2022 Nov;24(11):1521-1529
pubmed: 35781863
Int J Gynecol Cancer. 2021 Dec;31(12):1595-1601
pubmed: 34728527